Free Trial

Agenus (AGEN) Competitors

Agenus logo
$5.96 -0.08 (-1.32%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$5.93 -0.03 (-0.50%)
As of 07/25/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AGEN vs. ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, VSTM, VNDA, and CBIO

Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry.

Agenus vs. Its Competitors

Zenas BioPharma (NASDAQ:ZBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Zenas BioPharma presently has a consensus target price of $36.67, indicating a potential upside of 134.14%. Agenus has a consensus target price of $16.33, indicating a potential upside of 174.05%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Agenus
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Agenus had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for Agenus and 1 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.52 beat Agenus' score of 0.62 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Zenas BioPharma Very Positive
Agenus Positive

Zenas BioPharma has higher earnings, but lower revenue than Agenus. Zenas BioPharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$5M131.01-$156.99M-$3.55-4.41
Agenus$103.46M1.58-$227.21M-$8.67-0.69

Zenas BioPharma has a net margin of 0.00% compared to Agenus' net margin of -196.12%.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A N/A N/A
Agenus -196.12%N/A -82.33%

61.5% of Agenus shares are owned by institutional investors. 16.5% of Zenas BioPharma shares are owned by insiders. Comparatively, 5.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zenas BioPharma beats Agenus on 9 of the 14 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGEN vs. The Competition

MetricAgenusMED IndustryMedical SectorNASDAQ Exchange
Market Cap$165.60M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.6921.1828.1020.05
Price / Sales1.58288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book-0.468.378.665.87
Net Income-$227.21M-$55.19M$3.25B$258.55M
7 Day Performance-3.09%5.88%4.23%3.74%
1 Month Performance21.38%17.33%10.52%11.75%
1 Year Performance-9.15%4.42%34.41%18.03%

Agenus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGEN
Agenus
4.2207 of 5 stars
$5.96
-1.3%
$16.33
+174.0%
-0.1%$165.60M$103.46M-0.69440
ZBIO
Zenas BioPharma
1.6642 of 5 stars
$14.29
+4.1%
$36.67
+156.6%
N/A$597.75M$5M-4.03N/ANews Coverage
RGLS
Regulus Therapeutics
1.5038 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
LXRX
Lexicon Pharmaceuticals
2.5712 of 5 stars
$1.23
flat
$3.67
+198.1%
-52.8%$444.63M$31.08M-2.41140
MYGN
Myriad Genetics
4.6737 of 5 stars
$4.45
-0.4%
$14.38
+223.2%
-84.0%$410.20M$837.60M-3.972,700News Coverage
Positive News
EBS
Emergent Biosolutions
4.3367 of 5 stars
$6.93
+0.0%
$14.33
+106.8%
-48.2%$376.27M$1.04B-2.562,420News Coverage
Positive News
RIGL
Rigel Pharmaceuticals
3.2084 of 5 stars
$19.59
+4.2%
$36.40
+85.8%
+85.0%$350.07M$179.28M9.46160Positive News
XOMA
XOMA Royalty
4.011 of 5 stars
$25.48
-0.7%
$69.50
+172.8%
-10.7%$305.00M$28.49M-22.1610News Coverage
Analyst Upgrade
VSTM
Verastem
3.5296 of 5 stars
$5.10
-1.2%
$13.38
+162.3%
+106.7%$280.24M$10M-1.5950
VNDA
Vanda Pharmaceuticals
4.7402 of 5 stars
$4.66
-2.5%
$16.50
+254.1%
-22.9%$274.61M$198.77M-6.21290Upcoming Earnings
CBIO
Crescent Biopharma
3.2077 of 5 stars
$13.20
-1.0%
$25.67
+94.4%
N/A$258.06M$10K-0.2950High Trading Volume

Related Companies and Tools


This page (NASDAQ:AGEN) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners